The Global Fund has announced that it signed an access agreement with Gilead Sciences to procure lenacapavir, a twice-a-year injection that has a 99 per cent success rate in preventing HIV infection.
The agreement will allow GF to provide the drug cheaply to the countries that it currently supports.
Kenya is among the countries supported by GF, but how soon it receives the new drug will depend on, among other factors, how fast the Pharmacy and Poisons Board approves its use locally.
In October last year, the manufacturer, Gilead, had announced that it was prioritising initial registration in 18 countries with the highest HIV burden.
